Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes

Read post on prnewswire.com

- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the primary endpoint. - ASC30 achieved placebo-adjusted weight reduction of 4.4%, 3.8% and 4.0% from baseline for 40 mg, 60 mg and 80 mg, respectively and...